|
|
|
|
Simvastatin linked to myopathy
Pfizer has backed its high-selling cholesterol-lowering drug Lipitor (atorvastatin) amid a new warning by US regulators linking high doses of another statin, simvastatin, to increased risk of muscle injury.The US Food and Drug Administration (FDA) has...
|
|
|
EHSI closes funding agreement with Celulas Genetica
Emerging Healthcare Solutions, Inc.(Pinksheets:EHSI) announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is funded in full. EHSI has...
|
|
|
Emerging Healthcare Solutions Closes $1.8 Million Biotech Funding Commitment
Companies mentioned in this article: Emerging Healthcare Solutions, Inc.HOUSTON -- (BUSINESS WIRE) -- Emerging Healthcare Solutions, Inc. (Pinksheets:EHSI) announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in...
|
|
|
Emerging Healthcare Solutions Closes $1.8 Million Biotech Funding Commitment
HOUSTON--(BUSINESS WIRE)-- Emerging Healthcare Solutions, Inc.(Pinksheets:EHSI) announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is...
|
|
|
Emerging Healthcare Solutions Closes $1.8 Million Biotech Funding Commitment
HOUSTON--(BUSINESS WIRE)--Emerging Healthcare Solutions, Inc.(Pinksheets:EHSI - News) announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is...
|
|
|
Emerging Healthcare Solutions Closes $1.8 Million Biotech Funding Commitment
HOUSTON--(BUSINESS WIRE)--Emerging Healthcare Solutions, Inc.(Pinksheets:EHSI) announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is funded...
|
|
|
Emerging Healthcare Solutions Closes $1.8 Million Biotech Funding Commitment
HOUSTON--(BUSINESS WIRE)--Emerging Healthcare Solutions, Inc.(Pinksheets:EHSI) announced today that it has closed its funding agreement with Celulas Genetica. EHSI will lock in up to 20% of earnings produced by Celulas Genetica when the agreement is funded...
|
|
|
Pfizer has new data on Lipitor
A new analysis of research data found that a high dose of popular cholesterol pill Lipitor lowers the risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug's maker said Monday.Pfizer Inc. said the new...
|
|
|
LIPITOR: Pfizer has new data on medicine
A new analysis of research data found that a high dose of popular cholesterol pill Lipitor lowers the risk of heart attack and stroke in some patients with both heart disease and kidney disease, the drug's maker said Monday.Pfizer Inc. said the new...
|
|
|
3 Deadbeat Stocks to Clean Out of Your Portfolio
By Michael Shulman, Editor, ChangeWave Shorts Michael Shulman is the editor of ChangeWave Shorts, a newsletter advisory service that helps individual investors make money on the short side of the market.These stocks have no place in your portfolio and should...
|
|
|
Pharma Boosts Ad Spending 2%
TRENTON, N.J.(AP) - Pharmaceutical companies boosted their spending on ads directly targeting consumers by barely 2 percent last year, according to data compiled by The Nielsen Co. Drugmakers spent a combined $4.51 billion on ads for prescription medicines...
|
|
|
Growth in CVD drug usage to help generics
Big pharmaceutical companies will struggle to profit from the expanding cardiovascular disease market over the next decade despite growing drug usage, according to Datamonitor.New research by the independent business analyst predicts the CVD pharmaceuticals...
|
|
|
Intensive Statin Tx Cuts CVEs in Kidney Disease Patients
By Ed Susman, Contributing Writer, MedPage Today Published: March 18, 2010 Action Points * Explain to interested patients that this study by the manfacturer of atorvastatin (Lipitor) suggests that heart disease patients with kidney disease and who have...
|
|
|
Intensive Statin Use Shows Reduced Risk of Cardiovascular Events in High-Risk Patients
New data from two subanalyses of the Treating to New Targets (TNT) trial showed an increased dose of atorvastatin calcium (Lipitor), lowered cardiovascular events among high-risk patients with both coronary heart disease (CHD) and chronic kidney disease ...
|
|
|
Study cites Zocor risks
Reed/Bloomberg Mercks Zocor may put some patients at greater risk for muscle injury when taken at the highest approved dose, U.S.regulators said as part of a review of widely used cholesterol medicines. The risk of muscle harm includes the most serious...
|
|
|
Studies: Drugs don't reduce heart problems for diabetes patients
ATLANTA (AP) - Key results from a landmark federal study are in, and the results are disappointing for diabetics: Adding drugs to drive blood pressure and blood-fats lower than current targets did not prevent heart problems, and in some cases caused harmful...
|
|
|
Study cites Zocor risks
Reed/Bloomberg Mercks Zocor may put some patients at greater risk for muscle injury when taken at the highest approved dose, U.S.regulators said as part of a review of widely used cholesterol medicines. The risk of muscle harm includes the most serious...
|
|
|
Slo-Niacin(R), A Non-Prescription Dietary Supplement, Features Nicotinic Acid - The Most Effective Agent For I
Niacin, or nicotinic acid, when used under the care and monitoring of a healthcare provider, is the most effective agent available for increasing high-density lipoprotein (HDL), or 'good cholesterol (1).' HDL is known as 'good cholesterol' because it has...
|
|
|
Pfizer expects EU Lipitor extension approval in May - Reuters
_ Pfizer expects EU Lipitor extension approval in May - Reuters.
|
|
|
Pfizer expects EU Lipitor extension approval in May
LONDON, March 19 (Reuters) - Pfizer said it expects a positive decision by the end of May on the inclusion of new paediatric data on labelling in Europe for its cholesterol drug Lipitor after European drug regulators recommended the move.
|
|
|
Pfizer expects EU Lipitor extension approval in May
* Company expects formal approval by the end of May * Lipitor is world's biggest-selling drug LONDON, March 19 (Reuters) - Pfizer <PFE.N> said it expects a positive decision by the end of May on the inclusion of new paediatric data on labelling in...
|
|
|
Generic deals may still hold appeal for Pfizer
* Lost out on Ratiopharm to Teva's $5 bln bid * Faces revenue gaps when it loses Lipitor NEW YORK, March 18 - Pfizer Inc PFE.N may still be eager to buy generic drugmakers, after being outbid for Germany's Ratiopharm in an effort to shore up revenue as it...
|
|
|
Generic deals may still hold appeal for Pfizer
The world's largest drugmaker showed fiscal discipline in avoiding an even pricier attempt for Ratiopharm, which was won by Teva Pharmaceutical Industries Ltd for about $5 billion, analysts said.To me it speaks a little bit to more sound capital allocation...
|
|
|
Atorvastatin may cause insulin resistance in patients with hypercholesterolemia
Atorvastatin significantly increased fasting insulin and glycated hemoglobin levels among patients with hypercholesterolemia, study results indicated.Researchers from several U.S. and Korean sites enrolled patients with LDL 100 mg/dL from Gachon University...
|
|
|
Teva beats out Pfizer in generics takeover [The Day, New London, Conn.]
19--The world's largest generic-drug firm has beaten out Pfizer Inc., the world's largest research-based pharmaceutical company, by placing a $5 billion bid to take over a German generics manufacturer, according to the Reuters news service.The Israeli firm...
|
